Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery

Heart

Volumn 93, Issue 2, 2007, Pages 226-231

  Feringa, Harm H H ^a   Schouten, Olaf ^a   Dunkelgrun, Martin ^a   Bax, Jeroen J ^b   Boersma, Eric ^a   Elhendy, Abdou ^c   De Jonge, Robert ^a   Karagiannis, Stefanos E ^a   Vidakovic, Radosav ^a   Poldermans, Don ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABDOMINAL AORTA ANEURYSM; ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; STRESS ECHOCARDIOGRAPHY; VASCULAR SURGERY;

AGED; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; DOBUTAMINE; ECHOCARDIOGRAPHY, STRESS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SURVIVAL RATE; TIME FACTORS;

EID: 33846621525     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.093716     Document Type: Article

References (27)

1. Eagle KA, Berger PB, Calkins H, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Non-cardiac Surgery). Circulation 2002;105:1257-67.
2. Mangano DT, Browner WS, Hollander M, et al. Long-term cardiac prognosis following noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA 1992;268:233-9.
3. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341:1789-94.
4. Bartels C, Bechtel JF, Hossmann V, et al. Cardiac risk stratification for high-risk vascular surgery. Circulation 1997;95:2473-5.
5. Sprung J, Abdelmalak B, Gottlieb A, et al. Analysis of risk factors for myocardial infarction and cardiac mortality after major vascular surgery. Anesthesiology 2000;93:129-40.
6. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977;297:845-50.
7. Detsky AS, Abrams HB, McLaughlin JR, et al. Predicting cardiac complications in patients undergoing non-cardiac surgery. J Gen Intern Med 1986;1:211-19.
8. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999;100:1043-9.
9. Kertai MD, Boersma E, Klein J, et al. Optimizing the prediction of perioperative mortality in vascular surgery by using a customized probability model. Arch Intern Med 2005;165:898-904.
10. Boersma E, Poldermans D, Bax JJ, et al. DECREASE Study Group (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography). Predictors or cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA 2001;285:1865-73.
11. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
12. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004;6:257-60.
13. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87:464-9.
14. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
15. Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003;42:728-35.
16. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-74.
17. Schnabel R, Rupprecht HJ, Lackner KJ, et al. AtheroGene Investigators. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study, Eur Heart J 2005;26:241-9.
18. Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.
19. Yeh HM, Lau HP, Lin JM, et al. Preoperative plasma N-terminal pro-brain natriuretic peptide as a marker of cardiac risk in patients undergoing elective non-cardiac surgery. Br J Surg 2005;92:1041- 5.
20. Richards AM, Doughty R, Nicholls MG, et al. Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction, Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001;37:1781-7.
21. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-43.
22. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-81.
23. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-18.
24. Jemberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40:437-45.
25. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003;107:1848-51.
26. Eagle KA, Rihal CS, Mickel MC, et al. Cardiac risk of noncardiac surgery: influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program. Coronary Artery Surgery Study. Circulation 1997;96:1882-7.
27. McFalls EO, Ward HB, Moritz TE, et al. Coronary artery revascularization before elective major vascular surgery. N Engl J Med 2004;351:2795-2804.